Objective: To compare the effects of oral ferrous bisglycinate 25 mg iron/day vs. ferrous sulfate 50 mg iron/day in the prevention of iron deficiency (ID) and iron deficiency anemia (IDA) in pregnant women. Design: Randomized, double-blind, intention-to-treat study. Setting: Antenatal care clinic. Sample: 80 healthy ethnic Danish pregnant women.
Methods: Women were allocated to ferrous bisglycinate 25 mg elemental iron (Aminojern®) (n=40) or ferrous sulfate 50 mg elemental iron (n=40) from 15 to 19 weeks of gestation to delivery. Hematological status (hemoglobin, red blood cell indices) and iron status (plasma iron, plasma transferrin, plasma transferrin saturation, plasma ferritin) were measured at 15–19 weeks (baseline), 27–28 weeks and 36–37 weeks of gestation. Main outcome measures: Occurrence of ID (ferritin <15 μg/L) and IDA (ferritin <12 μg/L and hemoglobin <110 g/L).
Results: At inclusion, there were no significant differences between the bisglycinate and sulfate group concerning hematological status and iron status. The frequencies of ID and IDA were low and not significantly different in the two iron groups. The frequency of gastrointestinal complaints was lower in the bisglycinate than in the sulfate group (P=0.001). Newborns weight was slightly higher in the bisglycinate vs. the sulfate group (3601±517 g vs. 3395±426 g, P=0.09).
Conclusions: In the prevention of ID and IDA, ferrous bisglycinate was not inferior to ferrous sulfate. Ferrous bisglycinate in a low dose of 25 mg iron/day appears to be adequate to prevent IDA in more than 95% of Danish women during pregnancy and postpartum.
Brise H. Influence of meals on iron absorption in oral iron therapy. Acta Med Scand. 1962;171, suppl. 376: 39–45.
Drachenberg CD, Papadimitriou JC. Placental iron deposits: significance in normal and abnormal pregnancies. Hum Pathol. 1994;25:379–85.
Lund EK, Wharf SG, Fairweather-Tait SJ, Johnson IT. Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers. Am J Clin Nutr. 1999;69:250–5.
Marsál K, Persson P-H, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Pædiatr. 1996;85:843–8.
Milman N. Iron prophylaxis in pregnancy – general or individual and in which dose? Ann Hematol. 2006;85:821–8.
Milman N, Agger OA, Nielsen OJ. Iron supplementation during pregnancy. Effect on iron status markers, serum erythropoietin and human placental lactogen. A placebo controlled study in 207 Danish women. Dan Med Bull. 1991;38:471–6.
Milman N, Bergholt T, Eriksen L, Byg K-E, Graudal N, Pedersen P, et al. Iron prophylaxis during pregnancy — how much iron is needed? A randomized dose-response study of 20–80 mg ferrous iron daily in pregnant women. Acta Obstet Gynecol Scand. 2005;84:238–47.
Milman N, Byg K-E, Graudal N, Agger AO. Reference values for hemoglobin and erythrocyte indices during normal pregnancy in 206 women with and without iron supplementation. Acta Obstet Gynecol Scand. 2000;78:89–98.
Milman N, Clausen J, Byg K-E. Iron status in 268 Danish women aged 18–30 years. Influence of menstruation, method of contraception, and iron supplementation. Ann Hematol. 1998;76:13–9.
Milman N, Ibsen KK, Christensen JM. Serum ferritin and iron status in mothers and newborn infants. Acta Obstet Gynecol Scand. 1987;66:205–11.
Nordic Council of Ministers. Nordic Nutrition Recommendations. Scand J Nutr. 1996;40:161–5.
Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C. UK Guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2012;156:588–600.
Pedersen P, Melsen GV, Milman N. Frequencies of the hemochromatosis gene (HFE) variants C282Y, H63D and S65C in 6,020 ethnic Danish men. Ann Hematol. 2008;87:735–40.
Pineda O. Ashmead HDW. Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bisglycinate chelate. Nutrition. 2001;17;381–4.
Rossander-Hultén L, Brune M, Sandström B, Lönnerdal B, Hallberg L. Competitive inhibition of iron absorption by manganese and zinc in humans. Am J Clin Nutr. 1991;54:152–6.
Skikne B, Baynes RD. Iron absorption. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, editors. Iron metabolism in health and disease. London: Saunders; 1994:51–87.
Sölvell L. Oral iron therapy. Side effects. In: Hallberg L, Harwerth H-G, Vannotti A, editors. Iron deficiency. Pathogenesis, clinical aspects, therapy. London: Academic Press; 1970:573–83.
Swedish Society of Obstetrics and Gynecology. Mödrahälsovård, sexuell och reproduktiv hälsa. 2008; rapport nr 59:47–8.
Szarfarc SC, Cassana LMN, Fujimori E, Guerra-Shinohara EM, Oliveira IMV. Relative effectiveness of iron bis-glycinate chelate (Ferrochel) and ferrous sulphate in the control of iron deficiency in pregnant women. Archivos Latinoamericanos de Nutricion. 2001;51 suppl 1:42–7.
Thomsen JK, Prien-Larsen JC, Devantier A, Fogh-Andersen N. Low dose iron supplementation does not cover the need for iron during pregnancy. Acta Obstet Gynecol Scand. 1993;72:93–8.
Worwood M. Laboratory determination of iron status. In: Brock, JH, Halliday JW, Pippard MJ, Powell LW, editors. Iron Metabolism in health and disease. London: WB Saunders; 1994:449–76.
©2014 by Walter de Gruyter Berlin Boston.
